PMID- 36378678 OWN - NLM STAT- MEDLINE DCOM- 20221219 LR - 20230103 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 100 IP - 7 DP - 2022 Dec TI - Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30-day results. PG - 1291-1299 LID - 10.1002/ccd.30450 [doi] AB - BACKGROUND: Severe tricuspid regurgitation (TR) is independently associated with increased morbidity and mortality. Percutaneous transcatheter approaches may offer an alternative for patients not amenable to surgery. METHODS: TriCLASP is a prospective, single-arm, multicenter European post-market clinical follow-up study (NCT04614402) to evaluate the safety and performance of the PASCAL system (Edwards Lifesciences) in patients with severe or greater TR. At 30 days, a composite of major adverse events (MAEs) adjudicated by a clinical events committee, echocardiographic parameters adjudicated by core laboratory, and clinical, functional, and quality-of-life measures were evaluated. RESULTS: Mean age of the 74 enrolled patients was 80.3 years, with 58.1% female, 90.5% systemic hypertension, and 77.0% in New York Heart Association (NYHA) class III/IV. Mean Society for Thoracic Surgeons score (MV repair) was 9.0%. TR severity was significantly reduced at discharge (p < 0.001) and sustained at 30 days (p < 0.001), and 90.0% of patients achieved